Mabwell’s Denosumab Biosimilar Shows Similar Efficacy To Xgeva

The Phase III Trial Enrolled Solid Tumor Patients With Bone Metastasis

 
• By Urtė Fultinavičiūtė

Mabwell’s denosumab biosimilar MW032, which awaits approval in China, achieved similar efficacy and safety profiles as the originator Xgeva in oncology patients.

X-ray of inflamed hip bone
Mabwell has multiple international partnerships for its denosumab biosimilars • Source: Shutterstock

More from Biosimilars

More from Products